SCHEMBL3272136

SCHEMBL3272136

CCCCCc1cc(O)cc2c1C(=O)c1c(O)cc(O)cc1C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 6/20 0.54
MEN1 O00255 3/20 0.54
CYP3A4 P08684 3/20 0.54
MAPT P10636 3/20 0.54
KMT2A Q03164 3/20 0.54
TDP1 Q9NUW8 3/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 2/20 0.54
APEX1 P27695 2/20 0.54
MAPK1 P28482 2/20 0.54
TP53 P04637 2/20 0.54
ALOX15 P16050 2/20 0.54
TSHR P16473 2/20 0.54
NPC1 O15118 1/20 0.54
PTP4A3 O75365 1/20 0.54
GMNN O75496 1/20 0.54
LMNA P02545 1/20 0.54
ESR1 P03372 1/20 0.54
CYP1A1 P04798 1/20 0.54
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278923 0.95 ELANE (0.55) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL3277225 0.89 ELANE (0.58) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL31756856 0.82 ELANE (0.49) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL13862945 0.82 ALOX5 (0.59) MEN1CYP3A4MAPTKMT2ATDP1
SCHEMBL3277618 0.79 ELANE (0.54) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL16431638 0.77 ELANE (0.67) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL13499948 0.77 ELANE (0.59) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL29390162 0.77 ESR1 (0.77) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL5968219 0.77 ESR1 (0.77) ELANEMEN1CYP3A4MAPTKMT2A
SCHEMBL4923792 0.75 PTGS2 (0.61) MEN1CYP3A4MAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
US-7691418-B2 Composition for inhibiting or preventing the formation of a biofilm OYSTERSHELL NV (BE) 2010-04-06 US disclosed
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm OYSTERSHELL NV (BE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm NQO2, NFKBIA, CROCC ELANE 208/4885MEN1 3614/4885CYP3A4 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.